News Releases

Month Year

Su	Mo	Tu	We	Th	Fr	Sa
25	26	27	28	29	30	1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31	1	2	3	4	5

Cancel Go

Month Year

Su	Mo	Tu	We	Th	Fr	Sa
25	26	27	28	29	30	1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31	1	2	3	4	5

Cancel Go

Email Alerts

Year All Years 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 Keywords Go

Advanced Search

Keywords

  Search Headlines Only

From

To

Asset Types

 Photos  Video  Audio  Documents  Events  Standard

 Basic Search

• Jul 27, 2020

  Insmed to Host Second Quarter 2020 Financial Results Conference Call on Thursday, August 6, 2020
• Jul 24, 2020

  Insmed Receives Positive CHMP Opinion for ARIKAYCE Liposomal 590 mg Nebuliser Dispersion for the Treatment of NTM Lung Infections Caused by MAC in Non-CF Patients with Limited Treatment Options

  - If Approved, ARIKAYCE Will Be First and Only Therapy in the European Union for This Difficult-to-Treat Condition -
• Jul 7, 2020

  New NTM Treatment Guidelines Recommend Insmed's ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of Patients with Refractory MAC Lung Disease

  --First update to treatment guidelines in more than a decade, marking important milestone in patient care--
• Jul 6, 2020

  Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
• Jun 24, 2020

  Positive Results from Phase 2 WILLOW Study of Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis Presented at ATS Virtual Clinical Trials Session

  --Brensocatib Shown to Reduce Time to First Pulmonary Exacerbation and Reduce Rate of Exacerbations Versus Placebo--

Show 5102550100 per page

Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your
email alerts.

Sign Up

View the latest Insmed Investor Presentation

Download